TP53 and colorectal carcinoma: Additionally, APC mutations, oncogenic β‐catenin in the WNT signaling pathway [8], mutations of TP53, activation of the RAS/MAPK pathways, and mutations of RAS family members contribute to CRC progression [9, 10].